IL303954B2 - FIMH mutants, their compositions and uses - Google Patents

FIMH mutants, their compositions and uses

Info

Publication number
IL303954B2
IL303954B2 IL303954A IL30395423A IL303954B2 IL 303954 B2 IL303954 B2 IL 303954B2 IL 303954 A IL303954 A IL 303954A IL 30395423 A IL30395423 A IL 30395423A IL 303954 B2 IL303954 B2 IL 303954B2
Authority
IL
Israel
Prior art keywords
polypeptide
seq
fimh
amino acid
polynucleotide
Prior art date
Application number
IL303954A
Other languages
English (en)
Hebrew (he)
Other versions
IL303954B1 (en
IL303954A (en
Inventor
Jan Grijpstra
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Jan Grijpstra
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Jan Grijpstra, Eveline Marleen Weerdenburg, Jeroen Geurtsen, Kellen Cristhina Fae, Louris Jakob Feitsma filed Critical Janssen Pharmaceuticals Inc
Publication of IL303954A publication Critical patent/IL303954A/en
Publication of IL303954B1 publication Critical patent/IL303954B1/en
Publication of IL303954B2 publication Critical patent/IL303954B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL303954A 2021-01-12 2022-01-11 FIMH mutants, their compositions and uses IL303954B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof

Publications (3)

Publication Number Publication Date
IL303954A IL303954A (en) 2023-08-01
IL303954B1 IL303954B1 (en) 2024-12-01
IL303954B2 true IL303954B2 (en) 2025-04-01

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303954A IL303954B2 (en) 2021-01-12 2022-01-11 FIMH mutants, their compositions and uses

Country Status (12)

Country Link
US (3) US11725028B2 (https=)
EP (1) EP4277921A1 (https=)
JP (2) JP7532672B2 (https=)
KR (2) KR20250007029A (https=)
CN (1) CN116888140A (https=)
AR (1) AR124604A1 (https=)
AU (1) AU2022207740B2 (https=)
CA (1) CA3207841A1 (https=)
IL (1) IL303954B2 (https=)
MX (1) MX2023008251A (https=)
TW (1) TW202241929A (https=)
WO (1) WO2022153166A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
PE20241621A1 (es) * 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
JP2003505030A (ja) * 1999-07-15 2003-02-12 メディミューン，インコーポレーテッド ＦｉｍＨアドヘジンベイストワクチン
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP1299544A2 (en) 2000-07-07 2003-04-09 Medimmune, Inc. Fimh adhesin proteins and methods of use
EP1313502A4 (en) * 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
US20030199071A1 (en) 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
EP3294761A4 (en) * 2015-05-13 2019-04-03 University of Washington COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
CA3074593A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol Protein delivery to membranes
US20190275134A1 (en) * 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US20240027467A1 (en) * 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof

Also Published As

Publication number Publication date
US11725028B2 (en) 2023-08-15
CN116888140A (zh) 2023-10-13
MX2023008251A (es) 2023-07-26
JP7532672B2 (ja) 2024-08-13
TW202241929A (zh) 2022-11-01
US20220220159A1 (en) 2022-07-14
JP2024109576A (ja) 2024-08-14
IL303954B1 (en) 2024-12-01
AR124604A1 (es) 2023-04-12
AU2022207740B2 (en) 2024-06-06
US20230406890A1 (en) 2023-12-21
US12297238B2 (en) 2025-05-13
KR20250007029A (ko) 2025-01-13
IL303954A (en) 2023-08-01
JP2024502854A (ja) 2024-01-23
CA3207841A1 (en) 2022-07-21
KR102746713B1 (ko) 2024-12-24
KR20230125842A (ko) 2023-08-29
US20250289854A1 (en) 2025-09-18
AU2022207740A1 (en) 2023-06-29
AU2022207740A9 (en) 2024-09-05
EP4277921A1 (en) 2023-11-22
WO2022153166A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
IL303954B2 (en) FIMH mutants, their compositions and uses
FI4090363T3 (fi) FimH-mutantti, sen koostumuksia ja sen käyttö
TW541314B (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
KR101473271B1 (ko) 항균제
IL275468B1 (en) Incretin analogs and their use
DK2344178T3 (en) Peptide sequences, their branched form and their use for antimicrobial applications
JP2011528222A5 (https=)
RU2757426C2 (ru) Иммунногенный слитый белок
RU2660351C2 (ru) Антимикробные пептиды
JP2024109576A5 (https=)
HRP20171694T1 (hr) Novi pripravci i postupci
CA2927428A1 (en) Novel polypeptide and uses thereof
CN114745958A (zh) 新型保护性屏障组合物及其用途
CN112569183B (zh) 一种抗ctla-4抗体及融合蛋白的制剂
JP6464507B2 (ja) 抗ウイルス剤、および抗菌剤
JP2000063400A (ja) 抗菌ペプチド及びこれを有効成分とする抗菌剤
WO2009005798A8 (en) Antifungal formulation and method of preparation
WO2011060613A1 (zh) 人α-防御素5突变体多肽及其制备方法和应用
CN118930611B (zh) 一种用于维持头皮菌群健康的抗菌肽及其制备方法和应用
DK2088197T3 (en) Haemophilus influenzae antigens and corresponding DNA fragments
CN103874502B (zh) 用于控制病原体的氨基酸序列
CN118909071A (zh) 多肽cdpep-135及其应用
KR102698428B1 (ko) 유산균 유래 단백질과 대장암 타겟팅 펩타이드를 포함하는 융합 단백질 및 이의 용도
CN113999297B (zh) 一种抗菌肽hrNCM及其制备方法与应用
TW202334184A (zh) ＳａｐＢ蛋白質之修飾體、ＳａｐＢ蛋白質及其修飾體之配製方法，以及溶解ＳａｐＢ蛋白質或其修飾體之水溶液